QQQ   444.44 (-0.09%)
AAPL   171.18 (-1.23%)
MSFT   420.89 (-0.13%)
META   490.07 (-0.77%)
GOOGL   150.72 (-0.10%)
AMZN   180.87 (+0.58%)
TSLA   176.83 (-1.67%)
NVDA   903.04 (+0.06%)
NIO   4.66 (-0.21%)
AMD   181.65 (+1.15%)
BABA   72.32 (+1.02%)
T   17.57 (+0.11%)
F   13.20 (+1.07%)
MU   118.04 (-0.92%)
CGC   9.28 (-2.83%)
GE   176.19 (-2.18%)
DIS   122.70 (+1.42%)
AMC   3.84 (-11.52%)
PFE   27.83 (+0.18%)
PYPL   66.75 (+0.27%)
XOM   115.39 (+0.37%)
QQQ   444.44 (-0.09%)
AAPL   171.18 (-1.23%)
MSFT   420.89 (-0.13%)
META   490.07 (-0.77%)
GOOGL   150.72 (-0.10%)
AMZN   180.87 (+0.58%)
TSLA   176.83 (-1.67%)
NVDA   903.04 (+0.06%)
NIO   4.66 (-0.21%)
AMD   181.65 (+1.15%)
BABA   72.32 (+1.02%)
T   17.57 (+0.11%)
F   13.20 (+1.07%)
MU   118.04 (-0.92%)
CGC   9.28 (-2.83%)
GE   176.19 (-2.18%)
DIS   122.70 (+1.42%)
AMC   3.84 (-11.52%)
PFE   27.83 (+0.18%)
PYPL   66.75 (+0.27%)
XOM   115.39 (+0.37%)
QQQ   444.44 (-0.09%)
AAPL   171.18 (-1.23%)
MSFT   420.89 (-0.13%)
META   490.07 (-0.77%)
GOOGL   150.72 (-0.10%)
AMZN   180.87 (+0.58%)
TSLA   176.83 (-1.67%)
NVDA   903.04 (+0.06%)
NIO   4.66 (-0.21%)
AMD   181.65 (+1.15%)
BABA   72.32 (+1.02%)
T   17.57 (+0.11%)
F   13.20 (+1.07%)
MU   118.04 (-0.92%)
CGC   9.28 (-2.83%)
GE   176.19 (-2.18%)
DIS   122.70 (+1.42%)
AMC   3.84 (-11.52%)
PFE   27.83 (+0.18%)
PYPL   66.75 (+0.27%)
XOM   115.39 (+0.37%)
QQQ   444.44 (-0.09%)
AAPL   171.18 (-1.23%)
MSFT   420.89 (-0.13%)
META   490.07 (-0.77%)
GOOGL   150.72 (-0.10%)
AMZN   180.87 (+0.58%)
TSLA   176.83 (-1.67%)
NVDA   903.04 (+0.06%)
NIO   4.66 (-0.21%)
AMD   181.65 (+1.15%)
BABA   72.32 (+1.02%)
T   17.57 (+0.11%)
F   13.20 (+1.07%)
MU   118.04 (-0.92%)
CGC   9.28 (-2.83%)
GE   176.19 (-2.18%)
DIS   122.70 (+1.42%)
AMC   3.84 (-11.52%)
PFE   27.83 (+0.18%)
PYPL   66.75 (+0.27%)
XOM   115.39 (+0.37%)
NASDAQ:DMAC

DiaMedica Therapeutics (DMAC) Stock Price, News & Analysis

$2.79
+0.14 (+5.28%)
(As of 10:01 AM ET)
Today's Range
$2.73
$2.79
50-Day Range
$2.58
$3.23
52-Week Range
$1.46
$4.75
Volume
5,039 shs
Average Volume
41,637 shs
Market Capitalization
$105.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

DiaMedica Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
164.2% Upside
$7.00 Price Target
Short Interest
Bearish
0.56% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.33mentions of DiaMedica Therapeutics in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.17 out of 5 stars

Medical Sector

789th out of 939 stocks

Pharmaceutical Preparations Industry

365th out of 432 stocks

DMAC stock logo

About DiaMedica Therapeutics Stock (NASDAQ:DMAC)

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company develops treatments for neurological disorders and cardio-renal disease. Its lead candidate is DM199, a pharmaceutically active recombinant form of the kallikrein-1 protein for the treatment of acute ischemic stroke and other vascular diseases. It is also developing DM300 that is in preclinical stage of development for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

DMAC Stock Price History

DMAC Stock News Headlines

$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
DiaMedica Therapeutics (NASDAQ:DMAC) PT Lowered to $8.00
Recap: DiaMedica Therapeutics Q4 Earnings
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Tryp Therapeutics Inc. (TRYP.CN)
Q3 2023 DiaMedica Therapeutics Inc Earnings Call
Earnings Outlook For DiaMedica Therapeutics
See More Headlines
Receive DMAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/20/2024
Today
3/28/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DMAC
Fax
N/A
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$8.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+164.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-19,380,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.35 per share

Miscellaneous

Free Float
35,491,000
Market Cap
$100.59 million
Optionable
Optionable
Beta
1.72
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Dietrich John Pauls MBAMr. Dietrich John Pauls MBA (Age 53)
    President, CEO & Director
    Comp: $736.79k
  • Mr. Scott Kellen CPA (Age 59)
    CFO & Company Secretary
    Comp: $447.02k
  • Dr. Kirsten L. Gruis M.D. (Age 51)
    M.S., Independent Consultant
    Comp: $519.82k
  • Dr. Ambarish Shah Ph.D.
    Chief Technology Officer
  • Mr. Dominic R. Cundari (Age 73)
    Chief Commercial Officer
  • Ms. Julie VanOrsdel Daves CCRP
    Senior VP of Clinical Development Operations
  • Mr. David J. Wambeke
    Chief Business Officer
  • Dr. Lorianne K. Masuoka M.D. (Age 63)
    Chief Medical Officer

DMAC Stock Analysis - Frequently Asked Questions

Should I buy or sell DiaMedica Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DMAC shares.
View DMAC analyst ratings
or view top-rated stocks.

What is DiaMedica Therapeutics' stock price target for 2024?

2 Wall Street analysts have issued 1 year price targets for DiaMedica Therapeutics' stock. Their DMAC share price targets range from $6.00 to $8.00. On average, they anticipate the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 164.2% from the stock's current price.
View analysts price targets for DMAC
or view top-rated stocks among Wall Street analysts.

How have DMAC shares performed in 2024?

DiaMedica Therapeutics' stock was trading at $2.84 on January 1st, 2024. Since then, DMAC shares have decreased by 6.7% and is now trading at $2.65.
View the best growth stocks for 2024 here
.

Are investors shorting DiaMedica Therapeutics?

DiaMedica Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 212,600 shares, an increase of 8.3% from the February 29th total of 196,300 shares. Based on an average daily volume of 42,900 shares, the short-interest ratio is currently 5.0 days.
View DiaMedica Therapeutics' Short Interest
.

When is DiaMedica Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our DMAC earnings forecast
.

How were DiaMedica Therapeutics' earnings last quarter?

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) issued its earnings results on Wednesday, March, 20th. The company reported ($0.14) EPS for the quarter, hitting the consensus estimate of ($0.14).

What other stocks do shareholders of DiaMedica Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Pfizer (PFE), Vaxart (VXRT), Aldeyra Therapeutics (ALDX), Capricor Therapeutics (CAPR), Oncolytics Biotech (ONCY), Sesen Bio (SESN) and Sorrento Therapeutics (SRNE).

When did DiaMedica Therapeutics IPO?

DiaMedica Therapeutics (DMAC) raised $18 million in an IPO on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.

Who are DiaMedica Therapeutics' major shareholders?

DiaMedica Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.11%), Vanguard Group Inc. (2.11%), Paragon Associates & Paragon Associates II Joint Venture (1.32%), Northern Trust Corp (0.35%), Avantax Advisory Services Inc. (0.03%) and Simplex Trading LLC (0.00%). Insiders that own company stock include David J Wambeke, Dietrich John Pauls, Harry W Alcorn Jr, Koch Thomas Von, Randall Michael Giuffre, Richard D Pilnik and Scott Kellen.
View institutional ownership trends
.

How do I buy shares of DiaMedica Therapeutics?

Shares of DMAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DMAC) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners